Diagnosed With Azoospermia? You Still Have Options
Hearing that there is “no sperm in the semen” can feel like a dead end. It isn’t. Azoospermia, the complete absence of sperm in the ejaculate, affects roughly 1% of all men and 10–15% of men evaluated for infertility (Eisenberg et al., Nature Reviews Disease Primers, 2023). With the right evaluation and an experienced male fertility team, many of these men go on to have biological children.
At Maze Men’s Health, azoospermia is not treated as a single diagnosis with a single answer. It is treated as a puzzle to be solved, one that requires the right testing, the right expertise, and a plan built around you. That is why patients travel from across the country and around the world for care here.
What Is Azoospermia?
Azoospermia means no measurable sperm in the semen after a sample is spun down and examined under a microscope, confirmed on two separate semen analyses (Carson and Kallen, JAMA, 2021). It falls into two main categories, and telling them apart is the single most important step in treatment:
- Obstructive azoospermia (OA): Sperm production is normal, but a blockage, in the epididymis, vas deferens, or ejaculatory ducts, prevents sperm from reaching the ejaculate. This accounts for roughly 40% of cases (Omolaoye et al., Scientific Reports, 2022).
- Non-obstructive azoospermia (NOA): The testicles produce little or no sperm due to impaired spermatogenesis, genetic factors, or testicular failure. NOA is the more complex form and accounts for the majority of azoospermia cases (Zhou et al., PLOS One, 2025).
The distinction matters because obstruction can often be bypassed or corrected, while non-obstructive cases call for a different, more specialized strategy.
Why the Right Workup Changes Everything
A proper azoospermia evaluation looks far beyond a single semen analysis. According to the AUA/ASRM male infertility guideline, men with azoospermia should have a hormonal evaluation including follicle-stimulating hormone (FSH) and testosterone, along with a focused history and physical exam (AUA/ASRM Guideline, 2024). Additional testing may include:
- Genetic testing (karyotype and Y-chromosome microdeletion analysis), since conditions like Klinefelter syndrome and AZF microdeletions are important causes of NOA (Zhou et al., PLOS One, 2025).
- Imaging and seminal-tract evaluation to look for ejaculatory duct obstruction, seminal vesicle abnormalities, or congenital absence of the vas deferens (Avellino et al., Fertility and Sterility, 2019).
Getting this workup right is where experience shows. A rushed or incomplete evaluation can send a man toward the wrong treatment, or toward no treatment at all.
Azoospermia Treatment Options
Treatment is matched to the cause. Here is how the major pathways work.
1. Correcting blockages (obstructive azoospermia). When sperm production is healthy but blocked, the goal is to restore or bypass the obstruction. For ejaculatory duct obstruction, transurethral resection of the ejaculatory ducts (TURED) and newer endoscopic seminal-vesicle techniques can restore sperm to the ejaculate, with improvement in semen parameters reported in up to ~90% of appropriately selected patients (Abdel-Al et al., Journal of Endourology, 2022). Endoscopic seminal vesiculoscopy is a minimally invasive way to diagnose and treat seminal-tract disease through the natural anatomic pathway, with few complications (Han et al., Cell Biochemistry and Biophysics, 2013).
2. Surgical sperm retrieval. When sperm cannot reach the ejaculate, sperm can often be retrieved directly from the testicle and used with IVF/ICSI. For non-obstructive azoospermia, the AUA/ASRM guideline specifically recommends microdissection testicular sperm extraction (microTESE), a precision technique that uses an operating microscope to identify the tiny pockets of the testis most likely to contain sperm (Halpern et al., JAMA, 2022). Even in challenging cases such as Klinefelter syndrome, microTESE achieves higher retrieval rates than conventional methods (Wang et al., Reproductive Biology and Endocrinology, 2025).
3. Hormonal and medical optimization. Some men with NOA have hormonal imbalances that can be improved before surgery. Depending on the cause, clinicians may use aromatase inhibitors, hCG, or selective estrogen receptor modulators (SERMs), while avoiding exogenous testosterone, which suppresses sperm production and should never be prescribed to a man who wants to father a child (AUA/ASRM Guideline, 2024). In men with hypogonadotropic hypogonadism, gonadotropin therapy can actually restore sperm production (Eisenberg et al., Nature Reviews Disease Primers, 2023).
What Makes Maze Men’s Health Different
Azoospermia is exactly the kind of diagnosis that rewards specialization. The difference between a successful outcome and a missed one often comes down to how thoroughly the cause is investigated and how skilled the surgeon is at advanced retrieval techniques. Maze Men’s Health focuses specifically on male reproductive and sexual health, offering:
- A complete azoospermia workup under one roof, hormonal, genetic, and anatomic.
- Advanced surgical options, including microdissection-based sperm retrieval for the most difficult cases.
- A coordinated plan that connects seamlessly with IVF/ICSI so retrieved sperm can be used or frozen for the future.
Patients Travel From Around the World for This Care
Not every city has a clinic that performs advanced azoospermia surgery, and access to assisted reproduction varies widely between regions and countries (Zafar et al., Drugs, 2023). That is why men, and couples, travel to reach specialized male fertility centers. Maze Men’s Health regularly cares for patients from across the United States and abroad, with a workup and surgical timeline designed for people who are coordinating treatment from a distance.
If you have been told you have no sperm, a second, specialized opinion can change the entire picture.
Take the Next Step
A diagnosis of azoospermia is the beginning of the evaluation, not the end of the conversation. With modern testing and advanced sperm-retrieval techniques, fatherhood remains possible for many men once thought to have no options.
Sources
American Urological Association and American Society for Reproductive Medicine. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline (2020; Amended 2024). American Urological Association, 2024.
Halpern, Joshua A., Alexander M. Davis, and Robert E. Brannigan. “Diagnosis and Treatment of Infertility in Men.” JAMA, vol. 328, no. 20, 2022, pp. 2056–2057.
Eisenberg, Michael L., et al. “Male Infertility.” Nature Reviews Disease Primers, vol. 9, no. 1, 2023.
Carson, Sandra A., and Amanda N. Kallen. “Diagnosis and Management of Infertility: A Review.” JAMA, vol. 326, no. 1, 2021, pp. 65–76.
Zhou, F., et al. “Diagnostic Yield of Exome Sequencing in Nonobstructive Azoospermia (NOA): A Systematic Review and Meta-analysis.” PLoS One, 2025.
Avellino, Gabriella J., et al. “Transurethral Resection of the Ejaculatory Ducts: Etiology of Obstruction and Surgical Treatment Options.” Fertility and Sterility, vol. 111, no. 3, 2019.
Abdel-Al, Ibrahim, et al. “Long-Term Success Durability of Transurethral Resection of Ejaculatory Duct in Treating Infertile Men with Ejaculatory Duct Obstruction.” Journal of Endourology, vol. 36, no. 7, 2022.
Wang, X., et al. “Genetic and Epigenetic Insights into Non-obstructive Azoospermia: Mechanisms, Biomarkers, and Clinical Perspectives.” Reproductive Biology and Endocrinology, 2025.
Zafar, Muhammad I., et al. “Effectiveness of Nutritional Therapies in Male Factor Infertility Treatment: A Systematic Review and Network Meta-analysis.” Drugs, vol. 83, no. 6, 2023, pp. 531–546.
